-
公开(公告)号：US08071297B2
公开(公告)日：2011-12-06
申请号：US12095783
申请日：2006-11-23
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/573 , G01N2333/91215 , G01N2800/32 , G01N2800/52
摘要： The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease.
摘要翻译： 本发明涉及体外或体内诊断心血管疾病，特别是高血压，狭窄，血管闭塞和/或其他血栓事件的方法，其中编码人的核酸的位置950处的核苷酸 确定ARK2蛋白或人的样品的人ARK2蛋白的298位的氨基酸以及使用ARK2来开发和/或制备治疗心血管疾病的药物。
-
公开(公告)号：US20090239218A1
公开(公告)日：2009-09-24
申请号：US12095783
申请日：2006-11-23
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/573 , G01N2333/91215 , G01N2800/32 , G01N2800/52
摘要： The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease.
摘要翻译： 本发明涉及体外或体内诊断心血管疾病，特别是高血压，狭窄，血管闭塞和/或其他血栓事件的方法，其中编码人的核酸的位置950处的核苷酸 确定ARK2蛋白或人的样品的人ARK2蛋白的298位的氨基酸以及使用ARK2来开发和/或制备治疗心血管疾病的药物。
-
公开(公告)号：US20090149375A1
公开(公告)日：2009-06-11
申请号：US11908467
申请日：2006-03-20
IPC分类号： A61K38/16 , A61K31/7088 , C12Q1/68 , C12Q1/48 , C40B30/00
CPC分类号： A61K38/45
摘要： The present invention refers to the use of the Mst protein or a nucleotide sequence coding for the Mst protein for the treatment of a thromboembolic disorder and to a method of screening a modulator of the Mst protein or the nucleotide sequence coding for the Mst protein.
摘要翻译： 本发明涉及使用Mst蛋白或编码Mst蛋白的核苷酸序列来治疗血栓栓塞性疾病，以及筛选Mst蛋白的调节剂或编码Mst蛋白的核苷酸序列的方法。
-
4.发明申请Use of LIMK-1, its analogues and ligands for the production of a medicament against a thrombus formation or blood clotting disease 审中-公开使用LIMK-1，其类似物和配体用于生产抗血栓形成或血液凝固疾病的药物公开(公告)号：US20050175601A1
公开(公告)日：2005-08-11
申请号：US10991172
申请日：2004-11-17
CPC分类号： A61K38/45 , G01N33/86 , G01N2500/04 , G01N2500/10
摘要： The present invention relates to LIMK-1, a LIMK-1-analogue or LIMK-1 ligand for the binding to GPIIb and/or activation or inhibition of GPIIb/IIIa downstream signaling, for the production of a medicament for the prevention or treatment of a thrombus formation or blood clotting disease, methods of screening a LIMK-1 analogue or a LIMK-1 ligand and a method for producing a medicament for the treatment of a thrombus formation or blood clotting disease.
摘要翻译： 本发明涉及LIMK-1，用于结合GPIIb的LIMK-1类似物或LIMK-1配体和/或GPIIb / IIIa下游信号传导的活化或抑制，用于生产用于预防或治疗GPIIb / 血栓形成或血液凝固疾病，LIMK-1类似物或LIMK-1配体的筛选方法以及用于治疗血栓形成或血液凝固疾病的药物的制备方法。
-
5.发明授权Potassium channel mutants of the yeast Saccharomyces cerevisiae and their use for screening eukaryotic potassium channels 失效酵母酿酒酵母的钾通道突变体及其用于筛选真核钾通道的用途公开(公告)号：US07429449B2
公开(公告)日：2008-09-30
申请号：US09758036
申请日：2001-01-11
申请人： Ekkehard Leberer , Thomas Leeuw , Allegra Ritscher
发明人： Ekkehard Leberer , Thomas Leeuw , Allegra Ritscher
IPC分类号： C12Q1/68 , G01N33/53 , G01N33/569 , C12N1/00
CPC分类号： C07K14/395
摘要： The invention relates to processes for identifying inhibitors and activators of eukaryotic potassium channels, in which a mutated S. cerevisiae cell is used whose endogenous potassium channels TRK1, TRK2 and TOK1 are not expressed functionally, but which expresses heterologously a eukaryotic potassium channel to be studied. Other subject matters of the invention are mutated S. cerevisiae cells which do not express TRK1, TRK2 and TOK1, and the preparation and use of these mutated S. cerevisiae cells.
摘要翻译： 本发明涉及用于鉴定真核钾通道的抑制剂和活化剂的方法，其中使用其内源性钾通道TRK1，TRK2和TOK1在功能上不表达但是在异源表达待研究的真核钾通道的突变型酿酒酵母细胞 。 本发明的其它主题是突变的不表达TRK1，TRK2和TOK1的酿酒酵母细胞，以及这些突变的酿酒酵母细胞的制备和使用。
-
公开(公告)号：US20050037965A1
公开(公告)日：2005-02-17
申请号：US10893025
申请日：2004-07-16
申请人： Sebastian Barradeau , Eckart Bartnik , Joerg Czech , Andreas Klatt , Ekkehard Leberer , Thomas Leeuw
发明人： Sebastian Barradeau , Eckart Bartnik , Joerg Czech , Andreas Klatt , Ekkehard Leberer , Thomas Leeuw
CPC分类号： A61K38/17 , C07K16/44 , Y10T436/143333
摘要： The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.
摘要翻译： 本发明涉及使用p21激活的激酶（PAK）抑制剂来治疗关节疾病如骨关节炎或类风湿性关节炎或用于治疗关节疼痛，以及使用PAK作为靶蛋白来发现 PAK抑制剂作为治疗关节疾病的药物。
-
7.发明申请Potassium channel mutants of the yeast Saccharomyces cerevisiae and their use for screening eukaryotic potassium channels 审中-公开酵母酿酒酵母的钾通道突变体及其用于筛选真核钾通道的用途公开(公告)号：US20100167275A1
公开(公告)日：2010-07-01
申请号：US12121900
申请日：2008-05-16
申请人： Ekkehard Leberer , Thomas Leeuw , Allegra Ritscher
发明人： Ekkehard Leberer , Thomas Leeuw , Allegra Ritscher
CPC分类号： C07K14/395
摘要： The invention relates to processes for identifying inhibitors and activators of eukaryotic potassium channels, in which a mutated S. cerevisiae cell is used whose endogenous potassium channels TRK1, TRK2 and TOK1 are not expressed functionally, but which expresses heterologously a eukaryotic potassium channel to be studied. Other subject matters of the invention are mutated S. cerevisiae cells which do not express TRK1, TRK2 and TOK1, and the preparation and use of these mutated S. cerevisiae cells.
摘要翻译： 本发明涉及用于鉴定真核钾通道的抑制剂和活化剂的方法，其中使用其内源性钾通道TRK1，TRK2和TOK1在功能上不表达但是在异源表达待研究的真核钾通道的突变型酿酒酵母细胞 。 本发明的其它主题是突变的不表达TRK1，TRK2和TOK1的酿酒酵母细胞，以及这些突变的酿酒酵母细胞的制备和使用。
-
公开(公告)号：US08187828B2
公开(公告)日：2012-05-29
申请号：US12055511
申请日：2008-03-26
申请人： Sebastian Barradeau , Eckart Bartnik , Joerg Czech , Andreas R. Klatt , Ekkehard Leberer , Thomas Leeuw
发明人： Sebastian Barradeau , Eckart Bartnik , Joerg Czech , Andreas R. Klatt , Ekkehard Leberer , Thomas Leeuw
CPC分类号： A61K38/17 , C07K16/44 , Y10T436/143333
摘要： The invention refers to the use of a p21-activated kinase (PAK) inhibitor as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.
摘要翻译： 本发明涉及使用p21激活的激酶（PAK）抑制剂作为靶蛋白，用于发现PAK抑制剂作为治疗关节疾病的药物。
-
公开(公告)号：US07364887B2
公开(公告)日：2008-04-29
申请号：US10893025
申请日：2004-07-16
申请人： Sebastian Barradeau , Eckart Bartnik , Joerg Czech , Andreas R. Klatt , Ekkehard Leberer , Thomas Leeuw
发明人： Sebastian Barradeau , Eckart Bartnik , Joerg Czech , Andreas R. Klatt , Ekkehard Leberer , Thomas Leeuw
CPC分类号： A61K38/17 , C07K16/44 , Y10T436/143333
摘要： The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.
摘要翻译： 本发明涉及使用p21激活的激酶（PAK）抑制剂来治疗关节疾病如骨关节炎或类风湿性关节炎或用于治疗关节疼痛，以及使用PAK作为靶蛋白来发现 PAK抑制剂作为治疗关节疾病的药物。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.03 秒)
